Eli Lilly's Olumiant
Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
November 15, 2023 11:22 ET | Spherix Global Insights
Exton, Pennsylvania, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK...
Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4
Andira Pharmaceuticals Achieves Remarkable Breast Cancer Tumor Regression with Lead Oncology Candidate XOXO4
October 25, 2023 13:20 ET | US Capital Global
San Francisco, California, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million...
US Nephrologists Emb
US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
October 13, 2023 14:24 ET | Spherix Global Insights
Exton, Pennsylvania, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The FDA's recent approvals of Calliditas' Tarpeyo (budesonide) and Travere's Filspari (sparsentan) to treat primary IgA nephropathy (IgAN) have...
GMILogo_Vertical-Gradient.png
Psoriasis Treatment Market to hit USD 60.5 billion by 2032, says Global Market Insights Inc.
August 21, 2023 16:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Psoriasis Treatment Market size is expected to be worth USD 60.5 billion by 2032. The increasing R&D activities aimed at developing...
What’s on Your Must-
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
August 10, 2023 15:15 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...
Breaking Into a Satu
Breaking Into a Saturated Relapsing Remitting Multiple Sclerosis Market: Where Should Developers Focus?
August 01, 2023 12:02 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Despite outward appearances of being a stagnant market, the relapsing remitting multiple sclerosis (RMS) market continues to offer drug...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 14, 2022 08:45 ET | Palisade Bio, Inc.
Carlsbad, CA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc., (Nasdaq: PALI) a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
COVID Research
FHI Clinical to Write Clinical Trial Protocol for Development of Gb Sciences' COVID-19-Related, Anti-Inflammatory Therapies
May 02, 2022 09:00 ET | Gb Sciences
LAS VEGAS, May 02, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, announces that FHI Clinical Inc. will...
Logo.png
BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine
January 26, 2022 06:00 ET | BioRestorative Therapies, Inc
MELVILLE, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based...
BRT-logo-final.png
BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering
August 09, 2021 11:58 ET | BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it...